Voloridge Investment Management LLC Sells 329,710 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Voloridge Investment Management LLC reduced its position in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 31.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 729,416 shares of the life sciences company's stock after selling 329,710 shares during the period. Voloridge Investment Management LLC owned 0.95% of Integra LifeSciences worth $16,543,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the company. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Integra LifeSciences by 7.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company's stock worth $312,000 after purchasing an additional 913 shares during the period. Quadrant Capital Group LLC raised its position in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after acquiring an additional 1,371 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Integra LifeSciences by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company's stock worth $872,000 after acquiring an additional 1,437 shares in the last quarter. Sterling Capital Management LLC raised its position in shares of Integra LifeSciences by 821.7% in the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after acquiring an additional 1,931 shares in the last quarter. Finally, Covestor Ltd raised its position in shares of Integra LifeSciences by 61.8% in the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after acquiring an additional 2,071 shares in the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. JMP Securities decreased their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. JPMorgan Chase & Co. decreased their target price on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Truist Financial decreased their target price on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research report on Friday, April 11th. Wells Fargo & Company decreased their target price on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Finally, Argus upgraded shares of Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st. Four analysts have rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $18.63.

Integra LifeSciences Stock Performance

NASDAQ:IART traded down $0.16 during trading hours on Wednesday, reaching $12.96. The company had a trading volume of 132,223 shares, compared to its average volume of 1,039,988. The company has a current ratio of 1.20, a quick ratio of 0.73 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a 52 week low of $11.60 and a 52 week high of $32.66. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -144.10, a PEG ratio of 0.73 and a beta of 1.27. The firm's 50 day moving average price is $16.63 and its 200-day moving average price is $21.17.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its earnings results on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). The company had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue for the quarter was up 3.7% on a year-over-year basis. During the same period last year, the firm posted $0.55 EPS. On average, analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.